Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on March 31, 2004. The report addresses "Other Events" and incorporates by reference a press release issued on the same date regarding specific regulatory and legal developments.
Key Financial Metrics
The filing explicitly states that financial statements and pro forma financial information are inapplicable. Consequently, the document does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No financial material changes are reported in this filing. The document focuses on two non-financial events detailed in the attached press release:
- A submission regarding the pediatric use of the drug Paraplatin.
- A federal appeals court reversal concerning a patent.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or a discussion of general risks. The primary contingency noted is the legal status of a patent following a federal appeals court reversal and the regulatory status of a pediatric drug submission.
Investor Verification Checklist
- Verify the specific details of the federal appeals court reversal regarding the patent mentioned in the March 31, 2004 press release.
- Confirm the current status and potential timeline of the Paraplatin pediatric submission with the FDA.
- Review the full text of the attached press release (Exhibit 99) for qualitative impacts not summarized in the 8-K.